1.Society of Critical Care Medicine 2024 Guidelines on Adult ICU Design: An Interpretation
Hui ZHANG ; Jianhua SUN ; Wanchen ZHAO ; Lingli XIE ; Cong MA ; Yifan FANG ; Jing CAI ; Na GUO
Medical Journal of Peking Union Medical College Hospital 2026;17(2):421-428
This article provides a systematic interpretation and review of the
2.Cost-utility analysis of disitamab vedotin plus toripalimab as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma
Peiyan XIANG ; Hui ZHANG ; Kaixin ZHANG ; Guihao ZENG ; Bikun CAI ; Yuhang LIU ; Shuangshuang HU ; Yonghui LIU
China Pharmacy 2026;37(16):2138-2143
OBJECTIVE To evaluate the cost-utility of disitamab vedotin (DV) combined with toripalimab versus platinum-containing chemotherapy as first-line therapy for locally advanced or metastatic urothelial carcinoma(UC) with human epidermal growth factor receptor 2 (HER2) expression from the perspective of China’s health-care system.METHODS A cost-utility analysis was performed. A three-state partitioned survival model was constructed based on the RC48-C016 trial with a 1-week cycle length. The long-term health benefits [quality-adjusted life years(QALYs)] and costs of disitamab vedotin combined with toripalimab versus platinum-containing chemotherapy as first-line therapy for locally advanced or metastatic UC with HER2 expression were simulated. The simulation time horizon was set to 15 years, and the discount rate was 4.5%. The willingness-to-pay (WTP) threshold was defined as twice China’s per capita gross domestic product(GDP) in 2025 (199 330 yuan/QALY). The incremental cost-effectiveness ratio (ICER) between the two groups was compared, and one-way sensitivity analysis and probabilistic sensitivity analysis were conducted.RESULTS Compared with platinum-containing chemotherapy regimen, the DV plus toripalimab regimen yielded an additional 1.01 QALYs with an incremental cost of 183 224.45 yuan, and the ICER was 181 728.15 yuan/QALY, which was below the WTP threshold. At the current threshold, the probability that the DV combination regimen had a cost-utility advantage was 79.9%.CONCLUSIONS Taking twice China’s per capita GDP in 2025 as the WTP threshold, DV combined with toripalimab exhibits a cost-utility advantage over platinum-containing chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma.
3.Guidelines for the perioperative diagnosis and treatment of oncogene-driven non-small cell lung cancer (2026)
Weidong WANG ; Yongbin LIN ; Hui TIAN ; Gaofeng LI ; Shun XU ; Yongde LIAO ; Haitao MA ; Junfeng LIU ; Chundong GU ; Xiaolong YAN ; Shumin WANG ; Daqiang SUN ; Jianyang LIU ; Tao XUE ; Shaohua MA ; Zhigang LI ; Shuanghu YUAN ; Gen LIN ; Ling CAI ; Jianping ZHOU ; Wenzhao ZHONG ; Naixin LIANG ; Yi HAN ; Junfeng WANG ; Weidong ZHANG ; Xin WANG ; Lianjuan CHEN ; Lunxu LIU ; Xiuyi ZHI ; Lanjun ZHANG
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2026;33(09):1337-1353
Lung cancer constitutes the most prevalent and lethal malignant tumor in China. Approximately 85% of lung cancer diagnoses correspond to the non-small cell histological subtype [non-small cell lung cancer (NSCLC)]. Despite surgery being the mainstay for early-stage disease, postoperative recurrence remains high and adjuvant chemotherapy offers limited benefit. In recent years, targeted therapy has demonstrated substantial advantages in driver mutation-positive NSCLC. To this end, the Lung Cancer Medical Education Committee of the Chinese Medical Education Association developed guidelines based on a systematic review of evidence through November 2025, using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach and a modified Delphi method. Focusing on epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), and addressing ROS proto-oncogene 1 (ROS1), B-Raf proto-oncogene serine/threonine kinase (BRAF) V600E mutation, and mesenchymal-epithelial transition factor (MET) exon 14 (METex14) skipping, the guideline covers molecular testing, neoadjuvant/adjuvant therapy, perioperative strategies, minimal residual disease monitoring, and postoperative surveillance. It defines testing requirements, specifies stage-directed and subtype-specific treatments, and standardizes minimal residual disease monitoring. These recommendations emphasize precision and feasibility to improve survival and quality of life.
4.Advances in radiotherapy for first-line treatment of newly diagnosed advanced esophageal squamous cell carcinoma
Zeng HAI ; Wang XIAOFENG ; Bai HUI ; Zhang WEIJIA ; Cai JUN ; Yuan ZHIYONG
Chinese Journal of Clinical Oncology 2025;52(11):582-587
Owing to the insidious onset and limited awareness of early screening,many patients with esophageal squamous cell carcinoma(ESCC)are diagnosed at an advanced stage.Immunochemotherapy is the current standard first-line treatment for advanced ESCC;however,survival outcomes remain suboptimal.Radiotherapy,with its precise local control and potential immunomodulatory effects,is anticipated to act synergistically with immunochemotherapy,offering a novel direction for overcoming survival limitations.This review systematically sum-marizes the progress in the use of radiotherapy as a first-line treatment for advanced ESCC and discusses the synergistic mechanisms,clinical applications,and challenges associated with its combination with immunochemotherapy.
5.Development and application of a camelid single-domain antibody recognizing a linear B-cell epitope in glutamate dehydrogenase of Clostridium difficile
Huaqian ZHAI ; Zhezhou LI ; Mengting CAI ; Kai ZHANG ; Lijun SHEN ; Yongneng LUO ; Dazhi JIN ; Hui HU
Chinese Journal of Microbiology and Immunology 2025;45(8):629-635
Objective:To develop a camelid single-domain antibody (SdAb) recognizing linear B-cell epitopes in glutamate dehydrogenase of Clostridium difficile(CD-GDH), and to apply it in Western blot and ELISA. Methods:Purified recombinant CD-GDH was used as bait to screen phage-displayed camelid SdAb library and obtain positive clones. Then those clones were confirmed by Western blot, and their variable domain of heavy chain of heavy chain antibody(VHH) nucleotide sequence were determined. The VHH sequence was synthesized after codon optimization and cloned into the expression vector pET28a. The SdAb was then expressed and purified, and its ability to detect CD-GDH protein in multiple assays was further explored.Results:Six positive clones were obtained, among which clone GA4 was chosen for recombinant expression in Escherichia coli and further purification. The purified GA4 binded well with CD-GDH with a Kd value of 3 nmol/L. In Western blot and ELISA, GA4 was proven to be able to selectively detect both recombinant and endogenous CD-GDH. Conclusions:A camelid SdAb targeting a linear B-cell epitope in CD-GDH is successfully developed, which provides a very useful tool for detecting CD-GDH.
6.Study on quality standard of wine-processed Coptidis Rhizoma standard decoction
Huilin YANG ; Kaiwei HUANG ; Yanghua LI ; Suqin CAI ; Shuping XU ; Jiabao WEI ; Hui ZHANG ; Weizhi ZHAO ; Pei TAN
International Journal of Traditional Chinese Medicine 2025;47(9):1285-1292
Objective:To establish the quality standard of the standard decoction of wine-processed Coptidis Rhizoma by studying the extraction rate, fingerprint and component quantitative analysis.Methods:ccording to the Technical Requirements for Quality Control and Standard Formulation of Chinese Medicine Formula Granules, 15 batches of the standard decoction of wine-processed Coptidis Rhizoma were prepared, and the paste rate was determined; HPLC fingerprints of 15 batches of standard decoction of wine-processed Coptidis Rhizoma were established, and evaluated by combining similarity evaluation, clustering analysis, principal component analysis and orthogonal partial least squares discriminant analysis; the contents of berberine, epiberberine, pamadine, and safranine in the samples of the 15 batches were determined and analyzed their transfer rates.Results:A total of 15 batches of standard decoction samples were calibrated with 11 common peaks, referring to the recognition of 8 components. The similarity between the samples and the control product was greater than 0.900; the clustering analysis could cluster the 15 batches of samples into 2 classes; the results of the principal component analysis showed that the cumulative variance contribution rate of the 3 principal component factors was 89.388%; the OPLS-DA screened out the 3 components of the quality difference; the 15 batches of samples out of the paste rate was 15.7% -20.8%, and the mass fractions of berberine, epiberberine, safranine, and palmatine were 18.47%-24.38%, 2.82%-3.49%, 5.08%-6.69%, and 4.84%-6.68%, respectively, with transfer rates of 41.7%-61.7%, 46.9%-68.7%, 39.8%-61.5%, and 43.8%-65.2%.Conclusion:The fingerprint and content determination method established in this study is accurate, stable, simple, and can be used for the quality control and evaluation of the standard decoction of wine-processed Coptidis Rhizoma.
7.Report of 6 cases of lymphoproliferative disorders after liver transplantation
Hui ZHANG ; Yandong SUN ; Feng WANG ; Dan LIU ; Bin ZHUANG ; Jianhong WANG ; Dahong TENG ; Jinzhen CAI
Chinese Journal of Organ Transplantation 2025;46(2):161-165
This study reports the diagnosis and treatment of six cases of post-transplant lymphoproliferative disorder (PTLD) in liver transplant recipients, confirmed at the Affiliated Hospital of Qingdao University between August 2017 and May 2023. The report includes details on anti-rejection therapy, Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections, imaging findings, histopathological results, treatment courses, and prognoses. By summarizing the clinical experience in the diagnosis and management of PTLD following liver transplantation, this study aims to provide valuable insights and references for the clinical diagnosis and treatment of this condition.
8.ABO-incompatible liver transplantation for treating primary hepatic neuroendocrine tumor: a case report
Anhua DONG ; Yanfen DAI ; Yandong SUN ; Hui ZHANG ; Jinzhen CAI
Chinese Journal of Organ Transplantation 2025;46(3):232-234
Primary hepatic neuroendocrine tumor (PHNET) is an extremely rare subtype of neuroendocrine tumor (NET), accounting for approximately 0.3% - 4.0% of all NETs. This study reports a case of PHNET treated with ABO-incompatible liver transplantation. Intraoperatively, double filtration plasmapheresis was performed to remove antibodies. Postoperatively, the patient's blood concentrations of immunosuppressive drugs and liver function were closely monitored. The recipient maintained stable drug levels, with a gradual recovery of liver function. No acute rejection occurred, and the patient was successfully discharged.
9.Isolation,identification and genetic analysis of a three-lineage NADC30 PRRSV recombinant strain
Bingyan CAI ; Yangyang QIAO ; Tianxin LIU ; Weiyong ZUO ; Yongjuan WANG ; Kai ZHANG ; Hui LU ; Haiming WANG
Chinese Journal of Veterinary Science 2025;45(3):420-426
In June 2018,sows at a pig farm in Jiamusi,Heilongjiang Province,suffered a large num-ber of miscarriages,and subsequently weaned piglets at the farm began to show persistent high fe-ver symptoms at around 35 days of age,with some pigs having a fever of more than 41.5 ℃.In or-der to determine the cause of this outbreak,63 clinical samples from this farm were tested.The re-sults showed that 60 out of 63 samples were positive for the porcine reproductive and respiratory syndrome virus(PRRSV)antigen.Subsequently,PRRSV antigen-positive plasmid was transfected into African green monkey embryonic kidney cells(Marc-145),and after three generations of blind transmission,indirect immunofluorescence assay(IFA)was performed.The results showed that one PRRSV strain,named HLJ38,was successfully isolated.Then the whole genome of HLJ38 strain was sequenced and then analyzed in detail by bioinformatics software.Sequence analysis showed that there were three deletions of 131 amino acids(323-433 aa,483 aa and 504-522 aa)in the derived sequence of Nsp2 gene of HLJ38 strain,which was consistent with the molecular ge-netic marker of NADC30 PRRSV.The phylogenetic tree analysis showed that HLJ38 and NADC30 PRRSV in GenBank belong to lineage 1 subgroup,and the nucleotide homology of HLJ38 and NADC30 PRRSV in GenBank was only 85.2%and 84.6%.Recombinant analysis showed that HLJ38 was a recombinant NADC30-like PRRSV,and the recombinant gene fragments were de-rived from multiple strains,among which the fragment of 1-201 nt was provided by VR2332 strain and fragment of 6 641-8 061 nt derived from the HP-PRRSV strain.In summary,the re-sults showed that the outbreak in this pig farm may be caused by the recombination of PRRSV strains among different lineages,and the recombinant circulating strains not only have certain pathogenicity but also suggest that the existing commercial vaccines provide limited cross-protec-tion against them.Recombination between different lineages increases the genetic diversity of PRRSV and aggravates the difficulty of prevention and control of PRRS in pig farms.Therefore,it is necessary to continuously monitor the epidemic dynamics of PRRSV in pig farms and take effec-tive measures in time to curb the spread of PRRS.
10.Application of MALDI-TOF MS combined with serum separator tube and turbidimetry for direct identification of pathogens in sterile body fluids
Chinese Journal of Infection and Chemotherapy 2025;25(2):168-173
Objective To investigate the application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry(MALDI-TOF MS)combined with serum separator tube and turbidimetry in the direct identification of pathogens in sterile body fluids.Methods A total of 284 positive sterile body fluid specimens(blood,hydrothorax,ascites,bile,and cerebrospinal fluid)infected by a single pathogen with a blood culture instrument alarm time less than 48 h were collected from January to December 2023 in the Department of Laboratory Medicine at Suzhou Ninth People's Hospital.All the specimens were tested by turbidimeter for pathogen concentration.And the reliability of the identification results was judged by MALDI-TOF MS scores according to different concentrations of the main pathogens.Results The lowest concentration of microorganism for achieving reliable results was 3.0 mcf for Escherichia coli,2.0 mcf for Klebsiella pneumoniae,3.0 mcf for Staphylococcus aureus,3.5 mcf for Enterococcus faecalis and 4.0 mcf for Candida when identified by MALDI-TOF MS.The results were compared between VITEK 2 identification,routine MALDI-TOF MS identification,and direct MALDI-TOF MS identification.The results of routine MALDI-TOF MS identification and VITEK identification were consistent in 282 cases.The concentration greater than 1.7 was found in 272 cases with direct MALDI-TOF MS,and the sensitivity of MALDI-TOF MS was 95.8%(272/284).The results did not show significant difference between the 3 identification methods(x2=2.09,P=0.55).Conclusions MALDI-TOF MS combined with serum separator tube and turbidimetry is a reliable and innovative technique for identifying pathogens in sterile body fluids.It is rapid and accurate,and may be valuable for early etiological diagnosis in clinical practice.

Result Analysis
Print
Save
E-mail